Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RANITIDINE Cause Malignant neoplasm progression? 37 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 37 reports of Malignant neoplasm progression have been filed in association with RANITIDINE (Ranitidine). This represents 0.0% of all adverse event reports for RANITIDINE.

37
Reports of Malignant neoplasm progression with RANITIDINE
0.0%
of all RANITIDINE reports
6
Deaths
27
Hospitalizations

How Dangerous Is Malignant neoplasm progression From RANITIDINE?

Of the 37 reports, 6 (16.2%) resulted in death, 27 (73.0%) required hospitalization, and 2 (5.4%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RANITIDINE. However, 37 reports have been filed with the FAERS database.

What Other Side Effects Does RANITIDINE Cause?

Prostate cancer (60,641) Breast cancer (45,666) Colorectal cancer (45,528) Bladder cancer (41,984) Renal cancer (40,791) Oesophageal carcinoma (26,229) Gastric cancer (18,927) Hepatic cancer (17,818) Pancreatic carcinoma (15,752) Lung neoplasm malignant (15,214)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which RANITIDINE Alternatives Have Lower Malignant neoplasm progression Risk?

RANITIDINE vs RANITIDINE\RANITIDINE RANITIDINE vs RANOLAZINE RANITIDINE vs RAPAMUNE RANITIDINE vs RASAGILINE RANITIDINE vs RASBURICASE

Related Pages

RANITIDINE Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression RANITIDINE Demographics